GammaTile Dosimetry New Clinical Insights for Recurrent Brain Metastases

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=6cJDQLGML7o

GammaTile® Insights presents a panel of experts reviewing the latest GammaTile data published in Brachytherapy, August 2024. The multidisciplinary panel discusses the study’s findings that demonstrated GammaTile delivers higher therapeutic dose directly to the resection cavity while significantly reducing radiation exposure to surrounding healthy brain tissue compared to the highly targeted form of external beam radiation called stereotactic radiation therapy. • Keynote Speakers: • Moderator: • Peter F Orio III, DO, MS, FASTRO, FABS, Radiation Oncologist and Medical Director of Radiation Oncology, Dana-Farber Brigham Cancer Center • Panelists: • Daniel Kim, MD, MBA, Radiation Oncologist and Co-Director of Stereotactic Radiosurgery, Inova Brain and Spine Tumor Center • Michael McDermott, MD, Neurosurgeon and Chief Medical Executive, Neuroscience Institute • Ranjini Tolakanahalli, PhD, DABR, Director of Proton Physics, Miami Cancer Institute • Key Topics • Discussion of findings from T. Kutuk et al., Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastases resection cavities (Brachytherapy, 2024) • Dosimetric advantages for recurrent brain metastases – How GammaTile delivers a higher therapeutic dose to the resection cavity, while delivering a lower dose to the normal tissue compared to stereotactic radiation modalities as measured by V8, V10, and V24 metrics. • The benefits of surgical resection for treating recurrent brain metastases • Read the full article: https://doi.org/10.1016/j.brachy.2024... • About GT Medical Technologies, Inc. • Driven to raise the standard of care and improve the lives of patents with brain tumors, a team • of brain tumor specialists formed GT Medical Technologies. GammaTile is a Surgically Targeted • Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery. • GammaTile is FDA cleared as a treatment for patients with newly diagnosed malignant • intracranial neoplasms and patients with recurrent intracranial neoplasms. The potential for, • and symptoms of, adverse events related to radiation exposure vary depending on the • radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of • GammaTile(s). GammaTile Therapy should not be used for patients with known history of • hypersensitivity to bovine-derived materials. • Since its full market release in the United States in March 2020, GammaTile has been offered in • more than 100 hospitals, with more centers being added each month. For more information, • visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.

#############################

New on site